NEW YORK and ANN ARBOR, Mich., April 7, 2015 /PRNewswire/ — Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced that the Company will present preclinical research from its novel cancer immunotherapy program at the American Association of Immunologists (AAI) Annual Meeting, which will take place in New… Read More

NEW YORK and ANN ARBOR, Mich., Mar. 25, 2015 — Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced the achievement of a milestone under the Company’s collaboration agreement with Merck, known as MSD outside the United States and Canada, triggering an undisclosed payment. The program, announced in… Read More

NEW YORK and ANN ARBOR, Mich., March 18, 2015 /PRNewswire/ — Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced that the Company will present preclinical research from its novel cancer immunotherapy program at the American Association for Cancer Research (AACR) Annual Meeting, which will take place in… Read More

Selective RORγ agonist product candidates demonstrated activity as single agent therapy NEW YORK, NY; ANN ARBOR, Mich. – February 9, 2015 – Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced that promising data for the anti-tumor activity of the company’s oral, selective RORγ (“ROR gamma”) agonist product… Read More

ANN ARBOR, Mich. – February 2, 2015 – Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced that Bruce A. Goldsmith, Ph.D., Chief Business Officer, will present at the 17th Annual BIO CEO & Investor Conference on Tuesday, February 10, 2015, at 11:15 a.m. Eastern Time. The conference… Read More

Findings supporting novel approaches to inhibit or enhance immune responses for treating autoimmunity and cancer published in Nature Chemical Biology. ANN ARBOR, Mich. – Jan 5, 2015 – Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat autoimmune diseases and cancer, today announced publication of research showing that sterols and sterol sulfates formed during… Read More

Sterol metabolism controls Th17 differentiation by generating endogenous RORγ agonists… Read More

Results presented in poster presentation beginning today and in oral presentation Saturday November 8 at 1:40 PM at Society for Immunotherapy of Cancer annual meeting. ANN ARBOR, Mich. – November 7, 2014 – Lycera Corp., a biopharmaceutical company developing breakthrough oral immune modulators to treat autoimmune disease and cancer, today announced that data on the… Read More